Eastern Cooperative Oncology Group

30 total trials 3 currently recruiting 25 completed

Trial Pipeline

RECRUITING NA

The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials

NCT06756607

RECRUITING Phase 2

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

NCT05289687

RECRUITING NA

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

NCT05108298

ACTIVE NOT RECRUITING Phase 2

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01415752

ACTIVE NOT RECRUITING Phase 3

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

NCT00978458

COMPLETED Phase 2

Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

NCT01079780

COMPLETED Phase 2

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00274924

COMPLETED

Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

NCT00090974

COMPLETED Phase 3

Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer

NCT00060398

COMPLETED Phase 2

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

NCT00053209

COMPLETED Phase 3

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

NCT00027859

COMPLETED Phase 2

Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer

NCT00040807

COMPLETED Phase 2

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00041314

COMPLETED Phase 2

Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer

NCT00033657

COMPLETED Phase 3

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00028990

COMPLETED Phase 2

Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer

NCT00025350

COMPLETED Phase 2

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

NCT00006385

COMPLETED Phase 2

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00006008

COMPLETED Phase 2

Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer

NCT00005045

COMPLETED Phase 2

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

NCT00004223

COMPLETED Phase 2

PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer

NCT00003871

COMPLETED Phase 2

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

NCT00003308

COMPLETED Phase 2

Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors

NCT00003518

COMPLETED Phase 2

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

NCT00003129

COMPLETED Phase 3

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

NCT00003138

COMPLETED Phase 3

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

NCT00003150

COMPLETED Phase 3

Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

NCT00002868

COMPLETED Phase 2

Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix

NCT00003017

COMPLETED Phase 3

Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer

NCT00002888

COMPLETED NA

Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer

NCT00002667

What the Pipeline for Eastern Cooperative Oncology Group Shows

According to the ClinicalTrials.gov registry, Eastern Cooperative Oncology Group is linked to 30 US clinical trials across every stage of research activity. Of those, 3 studies are currently recruiting — about 10% of the sponsor's indexed portfolio — and 25 are already marked complete, representing roughly 83% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Eastern Cooperative Oncology Group reports 8 late-stage studies (Phase 3 and Phase 4 combined) and 18 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Eastern Cooperative Oncology Group is Bladder Cancer with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial